Dentons Paris has provided legal counsel to Bpifrance Large Venture in a recent $38 million funding round for Aqemia, a Paris-based biotech firm. This latest investment brings Aqemia's total funding to over $100 million since its founding.

The funding round was led by Cathay Innovation and included participation from Aqemia's existing investors, such as Wendel Growth, Eurazeo, Elaia, and Bpifrance Large Venture. Aqemia specializes in using artificial intelligence to discover therapeutic molecules and plans to utilize the new capital to enhance its global presence, initiate clinical trials, and focus on critical therapeutic areas like oncology, immunology, and central nervous system disorders.

Aqemia's strategy for international expansion includes opening an office in London, reflecting its ambition to establish itself as a global leader in biotech. This funding marks a pivotal moment in the company's growth, providing essential resources to further its mission of developing innovative medical solutions.

The Dentons team that advised Bpifrance Large Venture on this transaction included partner Olivia Guéguen, counsel Laura Godard, and associate Lisa Morand.

Dentons operates in over 80 countries, offering legal solutions that are both globally informed and locally relevant. The firm emphasizes a commitment to inclusion, diversity, equity, and sustainability, focusing on what matters most to its clients. For more information, visit www.dentons.com.